Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENERON PHARMACEUTICALS, INC.REGN · Entity 2010 | EVP General Counsel and Secret | August 19, 2026 | August 21, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENERON PHARMACEUTICALS, INC.
Report date August 19, 2026 · Filed August 21, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,373 |
Ending reported balance
After 2026-08-19 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-08-19 · Exercise / conversion · Acquired 12,282 · Balance 45,392 Row 2 · 2026-08-19 · Tax withholding · Disposed 9,019 · Balance 36,373 |
| Non-Qualified Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $381.92 · Expires 2026-12-16 | Direct | 12,283 |
Reported balance
After 2026-08-19 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-08-19 · Exercise / conversion · Disposed 12,282 · Balance 12,283 F1: The stock option award vested in four equal annual installments, commencing one year after the date of grant. |
| Common StockSEC Table I · non-derivative | IndirectBy 2024 GRAT | 3,402 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 3,402 |
| Common StockSEC Table I · non-derivative | IndirectBy 2025 GRAT | 5,407 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 5,407 |
| Common StockSEC Table I · non-derivative | IndirectBy 401(k) Plan | 413 |
Reported balance
Holding disclosure · report date 2026-08-19 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 413 |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option award vested in four equal annual installments, commencing one year after the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Merck & Co., Inc.
Report date November 17, 2003 · Filed November 18, 2003
Section 16 reporting ended · disclosed 2003-11-18. Current position is not established by this disclosure.
No balance rows disclosed in this filing.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 3,602 | $555.82 | $2,002,063.64 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 22 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,458 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 6,622 | $59.20 | $392,022.40 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 21 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,060 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 94 | $565.92 | $53,196.48 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 20 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,438 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 94 shares of Company stock on April 17, 2020 at prices ranging from $565.77 to $565.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 93 | $564.19 | $52,469.67 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 19 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,532 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 171 | $563.39 | $96,339.69 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 18 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,625 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 171 shares of Company stock on April 17, 2020 at prices ranging from $563.33 to $563.45. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 191 | $562.56 | $107,448.96 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 17 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,796 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 191 shares of Company stock on April 17, 2020 at prices ranging from $562.31 to $562.83. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 63 | $561.76 | $35,390.88 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 16 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,987 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 163 | $560.38 | $91,341.94 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 15 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,050 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 163 shares of Company stock on April 17, 2020 at prices ranging from $560.27 to $560.53. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 285 | $559.79 | $159,540.15 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 14 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,213 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 285 shares of Company stock on April 17, 2020 at prices ranging from $559.47 to $559.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 293 | $558.55 | $163,655.15 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 13 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,498 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 293 shares of Company stock on April 17, 2020 at prices ranging from $558.42 to $558.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 93 | $557.40 | $51,838.20 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 12 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,791 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 198 | $556.51 | $110,188.98 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 11 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,884 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 198 shares of Company stock on April 17, 2020 at prices ranging from $556.43 to $556.58. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 17, 2020 at each separate price. Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 114 | $555.10 | $63,281.40 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 10 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,082 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 104 | $552.85 | $57,496.40 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 9 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,196 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $550.00 | $3,300.00 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 8 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,300 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $549.24 | $54,924.00 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 7 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,306 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 99 | $548.27 | $54,278.73 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,406 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $547.00 | $54,700.00 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,505 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 5 | $542.31 | $2,711.55 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 4 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,605 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 17, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 95 | $541.94 | $51,484.30 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,610 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 23:27 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $59.20 | $0.00 |
DisclosureSEC source: 0001708138-20-000043 · edgardoc.xml · derivative · entry 8 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,933 Underlying: Common Stock · 5,000 shares Expires 2021-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,733 | $529.79 | $1,447,916.07 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,705 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 16, 2020 Filed Apr 20, 2020 23:26 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $59.20 | $296,000.00 |
DisclosureSEC source: 0001708138-20-000042 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 6 | $525.30 | $3,151.80 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 12 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,438 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 106 | $524.99 | $55,648.94 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 11 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,444 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 113 | $521.05 | $58,878.65 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 10 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,550 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 220 | $520.45 | $114,499.00 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 9 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,663 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 220 shares of Company stock on April 15, 2020 at prices ranging from $520.29 to $520.62. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 15, 2020 at each separate price. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 286 | $519.43 | $148,556.98 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 8 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,883 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 286 shares of Company stock on April 15, 2020 at prices ranging from $519.25 to $519.59. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 15, 2020 at each separate price. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 499 | $518.25 | $258,606.75 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 7 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,169 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 499 shares of Company stock on April 15, 2020 at prices ranging from $518.03 to $518.78. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 15, 2020 at each separate price. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 266 | $517.40 | $137,628.40 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 6 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,668 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 266 shares of Company stock on April 15, 2020 at prices ranging from $517.00 to $517.73. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 15, 2020 at each separate price. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 260 | $516.81 | $134,370.60 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 5 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,934 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 260 shares of Company stock on April 15, 2020 at prices ranging from $516.06 to $516.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 15, 2020 at each separate price. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 414 | $515.70 | $213,499.80 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 4 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,194 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 414 shares of Company stock on April 15, 2020 at prices ranging from $515.30 to $515.88. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 15, 2020 at each separate price. Read SEC document |
| April 15, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 92 | $514.63 | $47,345.96 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 3 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,608 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionNon-Qualified Stock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $59.20 | $0.00 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · derivative · entry 14 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,933 Underlying: Common Stock · 5,000 shares Expires 2021-09-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · derivative.exercise_date: The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Tax withholdingCommon Stock | 2,738 | $521.45 | $1,427,730.10 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 2 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,700 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 20:04 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | Exercise / conversionCommon Stock | 5,000 | $59.20 | $296,000.00 |
DisclosureSEC source: 0001708138-20-000038 · edgardoc.xml · nonDerivative · entry 1 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,438 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 100 | $497.32 | $49,732.00 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 20 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,438 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 210 | $496.50 | $104,265.00 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 19 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,538 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F14 · price: Represents volume-weighted average price of sales of 210 shares of Company stock on April 2, 2020 at prices ranging from $496.37 to $496.64. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 321 | $495.19 | $158,955.99 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 18 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,748 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F13 · price: Represents volume-weighted average price of sales of 321 shares of Company stock on April 2, 2020 at prices ranging from $495.09 to $495.24. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 111 | $494.36 | $54,873.96 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 17 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,069 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F12 · price: Represents volume-weighted average price of sales of 111 shares of Company stock on April 2, 2020 at prices ranging from $494.29 to $494.38. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 652 | $493.35 | $321,664.20 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 16 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,180 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F11 · price: Represents volume-weighted average price of sales of 652 shares of Company stock on April 2, 2020 at prices ranging from $493.01 to $493.54. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 521 | $492.62 | $256,655.02 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 15 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,832 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F10 · price: Represents volume-weighted average price of sales of 521 shares of Company stock on April 2, 2020 at prices ranging from $492.22 to $492.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 450 | $491.42 | $221,139.00 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 14 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,353 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F9 · price: Represents volume-weighted average price of sales of 450 shares of Company stock on April 2, 2020 at prices ranging from $491.13 to $491.70. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 484 | $490.32 | $237,314.88 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 13 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,803 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F8 · price: Represents volume-weighted average price of sales of 484 shares of Company stock on April 2, 2020 at prices ranging from $490.11 to $490.80. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 734 | $489.72 | $359,454.48 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 12 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,287 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F7 · price: Represents volume-weighted average price of sales of 734 shares of Company stock on April 2, 2020 at prices ranging from $489.31 to $489.98. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 1,626 | $488.26 | $793,910.76 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 11 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,021 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F6 · price: Represents volume-weighted average price of sales of 1,626 shares of Company stock on April 2, 2020 at prices ranging from $488.00 to $488.87. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 470 | $487.71 | $229,223.70 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 10 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,647 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F5 · price: Represents volume-weighted average price of sales of 470 shares of Company stock on April 2, 2020 at prices ranging from $487.32 to $487.97. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 485 | $486.61 | $236,005.85 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 9 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,117 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F4 · price: Represents volume-weighted average price of sales of 485 shares of Company stock on April 2, 2020 at prices ranging from $486.15 to $486.93. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 441 | $485.65 | $214,171.65 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 8 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,602 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F3 · price: Represents volume-weighted average price of sales of 441 shares of Company stock on April 2, 2020 at prices ranging from $485.01 to $485.89. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
| April 02, 2020 Filed Apr 3, 2020 20:08 UTC | REGENERON PHARMACEUTICALS, INC. REGN · Entity 2010 | SaleCommon Stock | 192 | $484.58 | $93,039.36 |
DisclosureSEC source: 0001708138-20-000026 · edgardoc.xml · nonDerivative · entry 7 LAROSA JOSEPH J · CIK 0001238303 · EVP General Counsel and Secret 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,043 F1 · kind: Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c). F2 · price: Represents volume-weighted average price of sales of 192 shares of Company stock on April 2, 2020 at prices ranging from $484.12 to $484.79. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on April 2, 2020 at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.